Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Island PharmaceuticalsASX:ILA 28 3-Year Book Growth Rate is 31.00% as of Jun. 2026. GuruFocus rates ASX:ILA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,128 Biotechnology companies, Island Pharmaceuticals ranks better than 89.18% on this metric.
During the past 12 months, Island Pharmaceuticals's average Book Value per Share Growth Rate was 50.00% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 31.00% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -11.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 6 years, the highest 3-Year average Book Value per Share Growth Rate of Island Pharmaceuticals was 31.00% per year. The lowest was -45.20% per year. And the median was -15.10% per year.
Island Pharmaceuticals (ASX:ILA) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Island Pharmaceuticals 3-Year Book Growth Rate Related Terms
ASX:ILA vs VRTX, REGN, MRNA: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Island Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Island Pharmaceuticals 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Island Pharmaceuticals's 3-Year Book Growth Rate falls into.
Island Pharmaceuticals 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 31.00% mean?
Island Pharmaceuticals (ASX:ILA) has a 3-Year Book Growth Rate of 31.00% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Island Pharmaceuticals and its competitors. According to the industry distribution chart, Island Pharmaceuticals ranks #122 out of 1128 companies in the Biotechnology industry, placing it in the top 10.8%.
Is Island Pharmaceuticals' 3-Year Book Growth Rate too high?
Island Pharmaceuticals' current 3-Year Book Growth Rate is 31.00%. Based on the distribution chart, Island Pharmaceuticals ranks #122 out of 1128 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Island Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' 3-Year Book Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Island Pharmaceuticals ranks #122 out of 1128 companies for 3-Year Book Growth Rate. This places Island Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Island Pharmaceuticals and its competitors. Island Pharmaceuticals's current 3-Year Book Growth Rate is 31.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current 3-Year Book Growth Rate of 31.00%. The current 3-Year Book Growth Rate is 31.00%. Island Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current 3-Year Book Growth Rate is 31.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
28GF Score
Get the complete analysis for ASX:ILA
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ILA has been successfully added to your 
